Menu

Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology

Bio-Techne invites you to join them for an educational webinar.

Feb 13, 2018
The Scientist Creative Services Team

Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology from thescientistllc on Vimeo.

Cell and tissue-based models are a necessary step in the workflow for toxicology testing, drug discovery, and disease modeling. In recent years, the research and pharmaceutical industries have adopted more-complex ex vivo and in vitro 3-D tissue models because of their better predictive power. In this webinar, representatives from Bio-Techne will discuss the history of cell- and tissue-based model systems for toxicology, drug screening, and disease modeling. They also introduce MimEX™ Tissue Model Systems, a transformative culturing platform that builds upon the physiological and structural advancements of current organoid models by producing 3-D tissue with better accessibility and lower variability. Tune in to learn more about MimEX 3-D Tissue.

Topics to be covered:

  • History of cell and tissue model systems for toxicology and disease modeling
  • Troubleshooting variability in iPSC-based models
  • Advantages and disadvantages of current 3-D culture systems

Meet the Speakers:

Scott Schachtele, PhD
Product Manager, Stem Cells and Cell Culture
Bio-Techne

 

 

Kevin Flynn, PhD
Scientist, Stem Cell Research and Development
Bio-Techne

 

 

Webinar Sponsored By:

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!